<DOC>
	<DOCNO>NCT00047697</DOCNO>
	<brief_summary>This 11-week study examine safety effectiveness medication donepezil ( AriceptÂ® ) compare placebo treat cognitive deficit child adolescent Autism Spectrum Disorder .</brief_summary>
	<brief_title>Drug Treatment Autism</brief_title>
	<detailed_description>Children autism spectrum disorder ( ASD ) often impaired communication , problem social interaction , repetitive stereotype pattern behavior . While research attempt treat behavioral deficit commonly associate ASD , study attempt improve core feature disorder . A recent study find donepezil HCl help improve speech production , attention span , ability express emotion group child autism . This study provide opportunity conduct test effect donepezil HCl cognitive deficit presume underlie core feature ASD . This study begin Week 1 baseline assessment . Participants randomly assign either donepezil HCl placebo . Participants start either 5mg/day dose donepezil HCl placebo follow cognitive assessment 4 week dose . Participants dose increase 10mg/day . Another cognitive assessment give 4 week dose .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Autism Spectrum Disorder ( ASD ) Asperger 's Disorder IQ 75 Baseline assessment test within acceptable range Bipolar disorder , schizophrenia , schizoaffective disorder , psychotic disorder Seizure disorder require use anticonvulsant medication Congenital rubella , cytomegalovirus , tuberous sclerosis Certain medication prescribe management behavior ( please contact investigator complete list ) Medications/preparations know interact donepezil HCl Significant medical illness , endocrinopathies , cardiovascular disease , severe chronic malnutrition Pregnancy sexually active female use reliable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>